Review Question - QID 109191

A 47-year-old female with a history of poorly controlled type I diabetes mellitus and end-stage renal disease undergoes an allogeneic renal transplant. Her immediate post-operative period is unremarkable and she is discharged from the hospital on post-operative day 4. Her past medical history is also notable for major depressive disorder, obesity, and gout. She takes sertraline, allopurinol, and insulin. She does not smoke or drink alcohol. To decrease the risk of transplant rejection, her nephrologist adds a medication known to serve as a precursor to 6-mercaptopurine. Following initiation of this medication, which of the following toxicities should this patient be monitored for?